ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

IMTX Immatics NV

9.82
0.00 (0.00%)
Pre Market
Last Updated: 04:05:06
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 9.30
Ask Price 15.61
News -
Day High

Low
7.15

52 Week Range

High
13.16

Day Low
Company Name Stock Ticker Symbol Market Type
Immatics NV IMTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 9.82 04:05:06
Open Price Low Price High Price Close Price Prev Close
9.82
Trades Volume Avg Volume 52 Week Range
0 0 - 7.15 - 13.16
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 9.82 USD

Immatics NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
752.9M 76.67M - 55.14M -96.99M -1.27 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Immatics NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IMTX Message Board. Create One! See More Posts on IMTX Message Board See More Message Board Posts

Historical IMTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.7811.149.7910.44473,207-0.96-8.91%
1 Month9.8412.559.7710.83520,832-0.02-0.20%
3 Months12.5013.169.6711.11480,976-2.68-21.44%
6 Months8.2013.168.1311.06473,9551.6219.76%
1 Year9.7513.167.1510.89463,7650.070.72%
3 Years11.3516.305.7510.43285,438-1.53-13.48%
5 Years17.2519.005.7511.08301,637-7.43-43.07%

Immatics NV Description

Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.

Your Recent History

Delayed Upgrade Clock